In a report released yesterday, Alex Arfaei from BMO Capital maintained a Hold rating on Bristol Myers (BMY). The company’s shares closed yesterday at $53.27.
According to TipRanks.com, Arfaei is a 5-star analyst with an average return of 8.8% and a 72.4% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Elanco Animal Health Inc, Merck & Company, and Eli Lilly & Co.
The word on The Street in general, suggests a Hold analyst consensus rating for Bristol Myers with a $59.13 average price target, an 11.0% upside from current levels. In a report issued on November 6, Morgan Stanley also maintained a Hold rating on the stock with a $59 price target.
.
See today’s analyst top recommended stocks >>
Bristol Myers’ market cap is currently $86.95B and has a P/E ratio of 60.53. The company has a Price to Book ratio of 6.37.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
